Prerpints.org logo
Preprint
Review

This version is not peer-reviewed.

Clinical Significance and Remaining Issues of Anti‐ HBc Antibody and HBV Core‐Related Antigen

A peer-reviewed article of this preprint also exists.

Submitted:

13 February 2024

Posted:

14 February 2024

You are already at the latest version

Abstract
Currently, hepatitis B virus (HBV) core antibody (anti-HBc antibody) and HBV core-related antigen (HBcrAg) are widely used as serum markers for diagnosis based on the HBV core region. While anti-HBc is very significant for clinical diagnosis, the clinical significance of quantitative assay of anti-HBc antibody has been reevaluated with improvements in diagnostic performance, including its association with clinical stage and prediction of carcinogenesis and reactivation. In addition, concerning the new HBcrAg, a high-sensitivity assay method has recently been established, and its diagnostic significance, including the prediction of reactivation, is being reevaluated. On the other hand, the quantitative level of anti-HBc antibody expressed in different units among assay systems, complicating the interpretation of the results. However, it is difficult to standardize assay systems as they vary in advantages, and caution is needed in interpreting the assay results. In this review, the clinical usefulness and remaining problems of anti-HBc antibody and HBcrAg were summarized.
Keywords: 
anti-HBc antibody
;  
HBV core-related antigen
;  
HBV
Subject: 
Medicine and Pharmacology  -   Gastroenterology and Hepatology

1. Introduction

The genome of hepatitis B virus (HBV) is an incomplete double-stranded circular DNA in which the minus strand (long strand) has a total length of approximately 3.2 kb, and 15-50% of the 3’-end of the plus strand (short strand) is lost. Four open reading frames (ORFs), i.e., the Pre-S/S gene, Pre-C/C gene, P (Pol) gene, and X gene, are present on the minus strand with partial overlapping [1]. Of the Pre-C/C gene, the C gene produces a core protein (HBc antigen) consisting of 183 to 185 amino acids. One hundred and twenty dimers of the core protein assemble to form a capsid. The C-terminus of the core protein contains an arginine-rich sequence, and the core protein binds to the viral nucleic acid (pre-genomic RNA) at this site to form a nucleocapsid [2,3]. The Pre-C region encoding 29 amino acids is connected upstream of the C gene in the same frame, and a pre-core precursor protein is produced from the Pre-C/C gene. Although the pre-core region is not essential for viral replication, it is thought to play an important role in evading host immunity (especially immunity against the core protein). HBe antigen detected in serum has clinical significance as an indicator of HBV infectivity, and the epitope of HBc antigen is considered an important region involved in cellular and humoral immune responses such as T cell proliferation and the production of anti-HBc antibody [4].

2.1. Clinical Significance of Anti-HBc Antibody

Since anti-HBc antibody appears relatively early in HBV infection and is maintained almost throughout life, it is a serological indicator widely used for detecting HBV-infected persons including those infected previously. For this reason, it has traditionally been considered useful for checking the safety of blood transfusion [5].
In recent years, quantitative anti-HBc antibody testing has become widespread, and many clinical findings have been reported regarding the assay results. In anti-HBc antibody, there are the anti-IgM type, which increases particularly in acute hepatitis B, and the anti-IgG type, which increases in chronic persistent infection. While the anti-IgM type HBc antibody also increases in the acute exacerbation period of chronic hepatitis, the titer is not considered high. It is reported that an IgM-HBc level with a S/CO ratio of ≥8 and an HBVDNA level of <5.5 logIU/mL are considered useful for the differentiation of acute hepatitis B (AHB) and acute exacerbation of chronic hepatitis B (CHB-AE) (sensitivity 98.1%, specificity 86.2%) [6]. Lall et al. also reported from India that an anti-IgM-HBc antibody level with a S/CO of ≥20.5 indicated AHB with a sensitivity of 93.3% and a specificity of 92.7% [7].

2.2. Assay and Units Using for Quantitative anti-HBc Antibody

The international reference standard is expressed in terms of IU/mL, but the current anti-HBc antibody assay has shifted from the competitive method to the double antigen sandwich assay with improvements in sensitivity. Anti-HBc antibody is assayed by techniques including enzyme-linked immunosorbent assay (ELISA), chemiluminescent microparticle immunoassay (CMIA), chemiluminescent immunoassay (CLIA), and chemiluminescent enzyme immunoassay (CLEIA) depending on the instrument used, and the results are presented in units such as IU/mL, INH%, and S/O, etc., so caution is needed in interpreting the assay results [8,9,10,11,12,13,14,15,16,17,18] (Table 1). The ORTHO® HBc ELISA test system (Ortho-Clinical Diagnostics, NJ, USA) has been used for a long time and shows good agreement in sensitivity and specificity with other assays [12]. MONOLISA anti-HBc EIA (Bio-Rad, CA, USA) is also used for epidemiological data in developing countries such as those in Africa, because it is an EIA method relatively easy to handle [11]. ADVIA Centaur® (Bayer Diagnostics, NY, USA) has been reported by Helden and Dati et al. to be useful since 2004 [8,9], and Cavalieri et al. also demonstrated high sensitivity and concordance rates using Murex and MONOLISA [10]. Some conventional anti-HBc antibody assay systems detect both IgM and IgG types, requiring caution. To clarify the difference between IgG and IgM types, reagents that detect only the IgG type have recently been developed. With Lumipulse HBcAb-II® (Fujirebio, Tokyo, Japan), which detects both the IgM and IgG types, the differentiation of acute and chronic hepatitis used to be considered difficult, but newer Lumipulse HBcAb-N® is reported to detect IgG antibody alone and to be unaffected by IgM antibody [13]. In January 2014, ADVIA Centaur® HBc Total 2 (HBcT2) was approved by the FDA and has been shown to be effective for differentiation between IgG and IgM types (available at https://www.accessdata.fda.gov/cdrh_docs/pdf21/P210019B.pdf).
All reagents widely used in the world today have sufficiently high sensitivity and specificity. Schmid et al. compared Elecsys® (Roche Diagnostics, Basel, Switzerland) and ARCHITECT® (Abbott Laboratories, IL, USA) assays using donated blood samples and found them useful for screening with a sensitivity of 100% and specificity of more than 95.5% [15]. Hottenträger et al. examined the sensitivity and specificity of the Elecsys® and ARCHITECT® assays in German samples and reported that both systems were useful, showing 99% or higher sensitivity and specificity [20]. Maugard et al. also studied the usefulness of Elecsys® in French donated blood samples and reported a good detection rate [21]. Hourfar and Schmidt et al. compared available HBc antibody assay systems and reported that the sensitivity and specificity of each kit were acceptable [15]. Li et al. used WANTAI's Diagnostics Kit (Wantai Biological Pharmacy Enterprise, Beijin, China) for antibody to hepatitis core antigen (ELISA) to confirm the presence of HBc antibody in various regions of China and assessed the risk of infection associated with blood transfusion [22].
Highly sensitive assay systems are being developed, but there is a risk of clinical meaninglessness or unnecessary anxiety for the examiner if the test result is a false positive. A German study of donated blood specimens using three types of HBc antibody tests (CMIA, EFLA, and ELISA) identified 117 of 109,603 specimens as “false positive” or “specificity confirmed” [23]. It is generally difficult to distinguish between false positives and true negatives in sample with low titer positives using quantitative testing, and improving the accuracy of assays is a future challenge. According to a report from Iran, it was reported that the response of anti-HBs antibody after HBV vaccination in previously infected individuals with isolated anti-HBc antibody positive was lower those with true negative individuals [24]. However, this finding is difficult to interpret because of the difference in age backgrounds.

2.3. Isolated Anti-HBc Antibody Positive

Among anti-HBc antibody-positive carriers, the HBsAg-negative and anti-HBs antibody-negative population is known as isolated anti-HBc (IAHBc) [25]. IAHBc can be a risk for HBV reactivation after organ transplantation, chemotherapy, or immunosuppressive therapy [26]. IAHBc is sometimes a risk for viral reactivation in immunosuppressive patients and is relatively common in dialysis and human immunodeficiency virus (HIV) infected patients [27,28,29]. Regarding the risk of IAHBc, there has been a report that viral mutations, such as sI92T, sQ129H, rtL80I, rtS85F, and rtL91I, are related [30] and a case control study involving Indonesians that suggested an involvement of genetic polymorphism of HLA-DP of the host [31]. The clinical importance of IAHBc has been suggested by a recent cohort study involving 609,299 Koreans, which reported that IAHBc was observed in 3.8% of the cohort and was a risk factor for liver-related death [32].

2.4. Anti-HBc Antibody in Patients with Acute/Chronic Hepatitis

Concerning the treatment for chronic hepatitis, there are a number of reports that the anti-HBc antibody level is related to the treatment response. Liao et al. reported that the risk of hepatitis increased when the anti-HBc antibody level was above a cut-off level of ≥4.0 log IU/mL in untreated CHB patients [33]. Fang et al. reported that the anti-HBc antibody level is useful for the prediction of response to interferon treatment in HBe antigen-positive CHB patients [34]. Wang et al. investigated the clearance of HBs antigen in patients treated with a nucleic acid analog preparation added on PEG-IFN and reported that the clearance rate of HBs antigen was high in patients with a low pre-treatment HBc antibody level [35]. Zhao et al. examined whether there was seroconversion of HBe antigen after the beginning of treatment with a nucleic acid analog and found that patients who showed serological response (HBe seroconversion) had a significantly higher pre-treatment HBc antibody level [36].
Recently, possible criteria for the discontinuation of nucleic acid analog therapy have been discussed, and high anti-HBc antibody (anti-HBc ≥1000 IU/mL: HR 0.31 per log IU/m) and low HBs antigen (HBsAg <100 IU/mL: HR 1.71 per log IU/m) are suggested to be factors of reduced clinical relapse [37].
The significance of anti-IgG-HBc antibody in AHB is not very clear, since elevation of anti-IgM-HBc antibody is followed by the appearance of anti-IgG-HBc antibody. Interestingly, using a mouse model, Wang et al. reported that anti-IgG-HBc antibody, which appears in an early stage of HBV infection, suppresses the increase in HBs antigen [38]. Also, the changes in anti-HBc antibody titer during CHB-AE have also not been sufficiently investigated. A recent report from China suggests that anti-HBc antibody is also useful for the prediction of prognosis of ACLF (acute-on-chronic liver failure). In this report, patients with a low anti-HBc antibody level at the onset of ACLF had a significantly worse prognosis [39]. There is room for further study on changes in the anti-HBc antibody level and the clinical significance in AHB and CHB-AE.
According to a report from Hong Kong, a cut-off value of 82.50 COI for anti-HBc antibody using Limipulse is a useful predictor of negative conversion of HBs antigen within 1 year [40]. A report from Taiwan also indicated that an anti-HBc antibody level of <3 log IU/mL is related to long-term seroclearance of HBs antigen [41].

2.5. Anti-Hbc antibody Positivity as A risk of Carcinogenesis

The relationship between anti-HBc antibody positivity and the risk of HCC is controversial. In 2010, Ohki et al. reported that the effect of anti-HBc antibody positivity was not statistically significant in HCV patients after exclusion of the effects of confounding factors such as being male and age [42]. In a Japanese study, Tsubouchi et al. also found no effect of anti-HBc antibody on HCC or liver-related deaths in HCV-positive individuals [43]. In 2011, it was reported from the USA that anti-HBc antibody positivity had no effect on carcinogenesis in hepatitis C patients [44]. On the other hand, in 2016, a meta-analysis including 26 original studies reported an increased risk of HCC with a HR of 1.36 for HBs antibody-positive/HBc antibody-positive cases and a HR of 2.15 for HBs antibody-negative/HBc antibody-positive cases compared to HBs antibody-negative/HBc antibody-negative individuals [45]. Among 8,513 HCV patients from a UK database, anti-HBc antibody positivity was also reported to increase the risk of liver cirrhosis with an HR of 1.29 and of HCC with an HR of 1.64 [46].
In a report from Hong Kong, Chan et al. reviewed 489 cases of NAFLD and 69 cases of NAFLD-related cryptogenic HCC. According to the report, in NAFLD cases, fibrosis was significantly more advanced when they were anti-HBc antibody-positive (cirrhosis was observed in 18.8% of anti-HBc antibody-positive cases and 7.5% of anti-HBc antibody-negative cases), and a high percentage (73.9%) of HCC cases were anti-HBc antibody-positive [47]. From Egypt, a country where HCV is endemic, El-Maksoud et al. reported that Genotype D was the major genotype and that anti-HBc antibody-positive cases were significantly younger and showed a higher histological grade of fibrosis [48]. Although there are various reports, race and ethnicity play major roles in the development of HCC, and further collection of information is considered necessary [49].

2.6. HBV Reactivation and Anti-HBc Antibody

When HBs antigen is eliminated in HBV carriers, anti-HBc antibody is the only serum marker for the detection of previous infection. Since fulminant hepatitis from occult HBV infection (OBI) is sometimes fatal [50,51], measurement of anti-HBc and anti-HBs antibodies along with HBs antigen is mandatory before immunosuppressive therapy [52,53,54]. In the treatment of malignant lymphoma, also, the higher the value on pretreatment HBc antibody testing, the higher the risk of reactivation, in HBs antigen-negative anti-HBc antibody-positive patients [55].
Although immune checkpoint inhibitors (ICIs) have been used for the treatment of many cancers in recent years, as of now, no OBI reactivation due to ICIs has been reported [56,57].
Clarke et al. used anti-TNF preparations in 120 HBs antigen-negative anti-HBc antibody-positive cases and found that positive conversion of HBs antigen occurred in only one case (0.8%), indicating a low frequency of reactivation [58].

2.7. Liver Transplantation for Anti-HBc Antibody-Negative Recipients

In 1998, Uemoto et al. reported that positive conversion of HBs antigen was observed in 16 of the 17 anti-HBs antibody-negative recipients of liver transplantation from anti-HBc antibody-positive donors [59]. Concerning liver transplantation, Joya-Vazquez et al. reported in 2002 that the risk of HBV reinfection was 2.5-fold higher with the use of anti-HBc antibody-positive grafts and that the risk of reinfection was reduced to one-fourth with treatment by lamivudine and HBIG [60]. According to a systematic review in 2010, also, transplantation from anti-HBc antibody-positive donors is basically safe, but HBV reinfection was observed in 11% of the recipients, and HBIG and lamivudine are recommended for anti-HBc antibody-negative recipients [61]. The authors further reported that de novo hepatitis occurred in 19% of liver transplantations from anti-HBc antibody-positive donors to HBs antigen-negative recipients, and that reactivation was observed in 15% of anti-HBc/HBs antibody-positive recipients and in 48% of HBV naïve recipients without prophylaxis, but that the risk of reactivation was greatly reduced under prophylaxis with HBIG, lamivudine, or their combination. On the other hand, the use of lamivudine and HBIG was shown to be associated with a high frequency of escaping mutations in anti-HBc antibody-negative recipients, and next-generation nucleic acid analogs are recommended [62]. Ueda et al. also reported that escape mutations were observed in 7 of 19 cases of de novo hepatitis and that lamivudine alone was not sufficient [63]. Subsequent advances in antiviral agents have largely eliminated the problem of antiviral-induced mutations after liver transplantation [64]. In 2019, a report from HK also evaluated long-term post-transplant outcomes of liver transplantations from 461 anti-HBc antibody-positive and 548 anti-HBc antibody-negative donors and showed that there was no difference in long-term prognosis, that de novo hepatitis observed in 3 of the 108 anti-HBc antibody-negative recipients all occurred during the time when lamivudine was used, and that such instances have recently been nearly eliminated [65]. In a report from Korea in 2021, the long-term prognoses of liver transplantation from 457 anti-HBc antibody-positive and 898 anti-HBc antibody-negative donors were examined, and even anti-HBc antibody-positive grafts were shown to have no impact on long-term survival. The same paper also reported that de novo hepatitis was observed in 0.9% of the transplants from anti-HBc antibody-positive donors to anti-HBc antibody-negative recipients [66].
There was a study that evaluated HBV reactivation after renal transplantation in 631 HBs antigen-negative HBc antibody-positive recipients. Reactivation was observed in 2 cases, and, although its frequency is low, caution is warranted [67].

2.8. Seroconversion to Anti-HBc Antibody Negative during Immunosuppressive State

In general, a person becomes anti-HBc antibody-positive throughout life after HBV infection, but both anti-HBc and anti-HBs antibodies may convert to negative under immunosuppressive conditions. Holtkamp et al. reported that permanent or intermittent anti-HBc loss was observed in 139 of 120,531 subjects by examination using Architect and that most of them were hematologic or solid tumor patients, organ transplant recipients, or HIV patients [68].
For anti-HBc antibody-positive patients, appropriate monitoring is required to prevent reactivation during anticancer and immunosuppressive therapies. The use of new agents, such as biologics and immune checkpoint inhibitors, has made it more important than ever to properly identify previously infected patients. Further data are also needed on negative conversion of anti-HBc antibody in the natural course of HBV infection.

3.1. Basics of HBV Core-Related Antigen

HBc antigen cannot be detected in blood because it is wrapped in the outer shell (envelope) and resides inside the HBV particle. HBcrAg is HBc antigen made more sensitively detectable together with the HBe antigen inside the core particle by degrading HBV core particles in blood to the smallest protein units (peptides). HBcrAg is the generic term for three antigenic component proteins: HBc antigen translated from pregenomic mRNA (hepatitis B core antigen), HBe antigen translated from precore mRNA (hepatitis B e antigen), and p22cr antigen (the 22 kDa procure protein) [69,70]. The HBcrAg assay system detects these three antigens together [71], and the results obtained have been shown to correlate well with hepatic cccDNA, HBVDNA, and HBs antigen levels [72,73,74,75,76].
A European research group, mainly based in France, also examined tissue samples from untreated chronic hepatitis B patients by Lumipulse G HBcrAg assay using the LUMIPULSE G1200 Analyzer (Fujirebio Europe, Gent, Belgium) and reported that serum HBcrAg correlates with hepatic HBVDNA, pgRNA, cccDNA, and transcriptional activity, indicating that HBcrAg can be an indicator of both hepatic cccDNA and transcriptional activity [77].
Recently, high-sensitivity assay of HBcrAg (iTACT-HBcrAg, cut-off value: 2.1 logIU/mL) has become possible [78]. By using a high-sensitivity system, the assay limit, which was previously 3.0-7.0 logU/mL, has been improved to 2.1-3.0 log U/mL (Table 2).

3.2. Stage of Chronic Hepatitis and HBV Core Related Antigen

The significance of HBcrAg in acute hepatitis has not been fully elucidated, but it has recently been reported that the kinetics of HBcrAg during acute hepatitis correlates roughly with HBe antigen and HBVDNA [79].
In the natural course of chronic hepatitis B, the disease progresses through the phases of immune tolerance (IT), immune clearance (IC), HBeAg-negative inactive/quiescent carrier (ENQ), and HBeAg-negative hepatitis (ENH). HBcr antigen has been shown to decrease with progression of the stage of chronic hepatitis, and a study of 294 HBV patients in China reported that the HBcrAg level was 9.30 log U/mL in IT, 8.80 log U/mL in IC, 5.10 log U/mL in ENH, and 3.00 log U/mL in ENQ, and that the cut-off values between IC and IT and between ENQ and ENH were 9.25 log U/mL and 4.15 log U/mL, respectively [80].
In HBe antigen-negative CHB in particular, the HBcrAg level is known to correlate well with markers such as ALT, APRL, and FIB4 [81]. Seto et al. examined 404 untreated patients by classifying them into IT, IC, ENH, ENQ, and HBsAg seroclearance, and reported that the HBcrAg level correlated well with the HBVDNA level, particularly, in ENQ group, that the positive rate was also high at 36.4% in the HBsAg-negative group, and that this sensitivity was comparable to that of HBsAg-HQ (22.7%) [82]. Also, in a European cohort, mainly from Germany, HBcrAg has been shown to reflect the disease status, with most cases in ENQ showing a HBcrAg level of less than 3.0 log U/mL [83]. Similarly, Loggi et al. also reported that, in HBe antigen-negative chronic hepatitis B, HBcrAg is useful in differentiation of the gray zone between active CHB and clinically quiescent infection (CIB), suggesting 2.5 log U/mL as the optimal cut-off level [84].
In a 96-week observational study in HK of 120 untreated patients treated with ETV and TDF, there was no significant difference in the reduction of HBcrAg (TDF vs. ETV: 2.28 vs. 1.65 log U/mL, p>0.05), but both drugs markedly reduced HBcrAg compared to the levels before the beginning of the treatment in the HBeAg-negative group (0.83 vs. 0.54 log U/mL, p>0.05) [85]. More recently, the risk of relapse of hepatitis after discontinuation of nucleic acid analogs (clinical relapse) has been reported to be reduced to HR 0.41 when the HBcrAg level is less than 3.0 log U/mL [86].
The additional clinical significance of the HBcrAg assay in CHB is not yet fully understood [81]. Also, as the false positive rate in CHB is 9.3%, and the false negative rate is 12-35%, caution is considered necessary in interpreting the results [87].

3.3. HBcrAg as a Predictor of Hepatocarcinogenesis

Since HBcrAg correlates well with cccDNA in the liver, many reports have been published on HBcrAg as a predictive marker for hepatocarcinogenesis. Kaneko et al. suggested that the HBcrAg level 1 year after the beginning of treatment with a nucleos(t)ide analogue preparation contributes to the risk assessment of carcinogenesis in HBe antigen-negative CHB patients and reported a HR of 6.749 with a cut-off level of 4.1 log U/mL [88]. Similarly, by analyzing 1,400 CHB patients taking nucleotide analogues, Liang et al. reported that the risk of carcinogenesis increases 2.13-fold with a HBcrAg cut-off level of 2.9 log U/mL in HBe antigen-negative patients [89]. In an observational study of 1,108 cases of HBV-associated cirrhosis and 219 cases of advanced HCC in Taiwan with a median follow-up period of 6.85 years, Chang et al. found that HR of the development of HCC was 1.70 with HBcrAg of 3.4-4.9 log U/mL and 2.14 with HBcrAg of >4.9 log U/mL, compared with HBcrAg of ≤3.4 log U/mL, that the risk assessment using HBcrAg was useful particularly when the HBsAg-HQ level was <3x107 mIU/mL [90]. Tseng et al. reported that HBcrAg is an independent risk factor for the development of hepatocarcinoma and that patients with an intermittent viral load of HBVDNA 2,000-19,999 IU/mL have an increased risk of carcinogenesis if HBcrAg is 4.0 log U/mL even with a normal ALT level [91]. It has also been reported that HBcrAg can be a risk for hepatocarcinogenesis even if HBVDNA is below the detection sensitivity limit during antiviral therapy [92,93,94,95]. Hosaka et al. observed 1,268 chronic hepatitis B patients treated with nucleic acid analogs for more than 1 year for a median follow-up period of 8.9 years and reported that 113 cases developed HCC, that the HBcrAg level during treatment is a risk factor for the progression of HCC, and that HR was 6.15 with a cut-off level of 4.9 log U/L in HBe antigen-positive patients and 2.54 with cut-off level of 4.4 log U/mL in HBe antigen-negative patients [94]. In Taiwan, 11.1% of patients with nonB-nonC HCC were HBcr antigen-positive, indicating that examination of HBcrAg is effective for risk screening in HBV endemic areas [92]. Recently, Hosaka et al. reported using a high-sensitivity HBcrAg assay system that the lower the measured value of HBcrAg 1 year after the beginning of oral administration of nucleos(t)ide analogues, the lower the incidence of HCC [96].

3.4. HBV Reactivation and HBcrAg

Recently, a high-sensitivity HBcr antigen assay system (iTACT-HBcrAg, cut-off value: 2.1 log IU/mL) has become available [78]. Its use reduced the lower limit of assay, which used to be 2.9 log U/mL, to 2.0 (Table 2). Hagiwara et al. evaluated the usefulness of the assay system using actual samples from patients with HBV reactivation. The results showed that iTACT-HBcrAg had a significantly higher detection rate than HBsAg-HQ (96% vs. 52%, respectively) and suggest that the HBcrAg level may become a surrogate marker for HBV reactivation [97]. Recently, the performance of iTACT-HBcrAg has been compared with that of a high-sensitivity HBs antigen assay system (iTACT-HBsAg) using samples from patients with HBV reactivation, indicating a higher sensitivity of iTACT-HBcrAg than iTACT-HBsAg (96.3% vs. 88.9%) [98].

4. Conclusions

Capsid assembly modulators (CAMs) targeting the core region have been shown to suppress pregenomic RNA and reduce cccDNA [99,100]. CAMs are expected to be novel therapeutic agents against HBV [101,102,103,104,105]. It is hoped that knowledge of the HBV core region will continue to increase in the future.

Author Contributions

Conceptualization, I.S. and Y.Y.; investigation, T.I.; data collection, I.S., and R.Y.; writing—original draft preparation, Y.Y.; writing—review and editing, T.M.; supervision, Y.U. and Y.K.; All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Grants-in Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan (22K16044, and 23K16795).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data are contained within the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

HBV: hepatitis B virus; HBc: hepatitis B virus core; HBcrAg: hepatitis B virus core-related antigen; pgRNA: pregenomic RNA; cccDNA: covalently circular closed DNA; ORF: open reading frame; Ig: immunoglobulin; CHB: chronic hepatitis B; CIB: clinically quiescent infection; AHB: acute hepatitis B; AE: acute exacerbation; ACLF: acute-on-chronic liver failure; EIA: enzyme immunoassay; ELISA: enzyme-linked immunosorbent assay; CMIA: chemiluminescent microparticle immunoassay; CLIA: chemiluminescent immunoassay; CLEIA: chemiluminescent enzyme immunoassay; COI: cut-off index; S/CO: sample cut-off; IU: international units; IAHBc: isolated anti-HBc antibody; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HIV: human immunodeficiency virus; NAFLD: non-alcoholic fatty liver disease; HBIG: hepatitis B immunoglobulin; ICI: immune checkpoint inhibitor; IT: immune tolerance; IC: immune clearance; ENQ: HBeAg-negative inactive/quiescent carrier; ENH: HBeAg-negative hepatitis; TDF: tenofovir; ETV: entecavir; CAM: capsid assembly modulator.

References

  1. Galibert, F.; Mandart, E.; Fitoussi, P.; Tiollais, P.; Charnay, P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979, 281, 646–650. [Google Scholar] [CrossRef]
  2. Tiollais, P.; Pourcel, C.; Dejean, A. The hepatitis B virus. Nature 1985, 317, 489–95. [Google Scholar] [CrossRef]
  3. Viswanathan, U.; Mani, N.; Hu, Z.; Ban, H.; Du, Y.; Hu, J.; Chang, J.; Guo, J.-T. Targeting the multifunctional HBV core protein as a potential cure for chronic hepatitis B. Antivir. Res. 2020, 182, 104917. [Google Scholar] [CrossRef]
  4. Milich, D.R.; McLachlan, A. The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen. Science 1986, 234, 1398–1401. [Google Scholar] [CrossRef]
  5. Roth, W.K.; Weber, M.; Petersen, D.; Drosten, C.; Buhr, S.; Sireis, W.; Weichert, W.; Hedges, D.; Seifried, E. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002, 42, 869–875. [Google Scholar] [CrossRef]
  6. Park, J.W.; Kwak, K.M.; Kim, S.E.; Jang, M.K.; Kim, D.J.; Lee, M.S.; Kim, H.S.; Park, C.K. Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients. World J. Gastroenterol. 2015, 21, 3953–3959. [Google Scholar] [CrossRef]
  7. Lall, S.; Agarwala, P.; Kumar, G.; Sharma, M.K.; Gupta, E. The dilemma of differentiating between acute hepatitis B and chronic hepatitis B with acute exacerbation: is quantitative serology the answer? Clin. Mol. Hepatol. 2020, 26, 187–195. [Google Scholar] [CrossRef]
  8. Van Helden, J.; Denoyel, G.; Karwowska, S.; Reamer, R.; Schmalz, J.; Wright, T.; Preisel-Simmons, B. Performance of hepatitis B assays on the Bayer ADVIA Centaur Immunoassay System. Clin. Lab. 2004, 50, 63–73. [Google Scholar]
  9. Dati, F.; Denoyel, G.; van Helden, J. European performance evaluations of the ADVIA Centaur® infectious disease assays: requirements for performance evaluation according to the European directive on in vitro diagnostics. J. Clin. Virol. 2004, 30, S6–S10. [Google Scholar] [CrossRef]
  10. Cavalieri, S.J.; Hrabovsky, S.; Jorgensen, T. Comparison of DiaSorin and Bio-Rad Test Kits for the Detection of Hepatitis B Virus Total Core and Surface Antibodies on the Bio-Rad Evolis. Am. J. Clin. Pathol. 2010, 133, 110–113. [Google Scholar] [CrossRef] [PubMed]
  11. Mahgoub, S.; Candotti, D.; El Ekiaby, M.; Allain, J.-P. Hepatitis B Virus (HBV) Infection and Recombination between HBV Genotypes D and E in Asymptomatic Blood Donors from Khartoum, Sudan. J. Clin. Microbiol. 2011, 49, 298–306. [Google Scholar] [CrossRef]
  12. Schmidt, M.; Nübling, C.M.; Scheiblauer, H.; Chudy, M.; Walch, L.A.; Seifried, E.; Roth, W.K.; Hourfar, M.K. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang. 2006, 91, 237–243. [Google Scholar] [CrossRef] [PubMed]
  13. Choi, S.J.; Park, Y.; Lee, E.Y.; Kim, S.; Kim, H.-S. Performance Evaluation of LUMIPULSE G1200 Autoimmunoanalyzer for the Detection of Serum Hepatitis B Virus Markers. J. Clin. Lab. Anal. 2013, 27, 204–206. [Google Scholar] [CrossRef] [PubMed]
  14. Lee, T.; Yang, J.J.; Eom, J.; Kwon, S.; Park, B.G.; Hwang, S.-H.; Oh, H.-B. A single-center, single-blind study to evaluate the clinical sensitivity, specificity, and agreement between Elecsys Anti-HBc II and Elecsys Anti-HBc in a Korean population. J. Clin. Virol. 2018, 109, 41–44. [Google Scholar] [CrossRef] [PubMed]
  15. Schmidt, M.; Jimenez, A.; Mühlbacher, A.; Oota, S.; Blanco, L.; Sakuldamrongpanich, T.; Schennach, H.; Seifried, E. Head-to-head comparison between two screening systems for HBsAG, anti-HBc, anti-HCV and HIV combination immunoassays in an international, multicentre evaluation study. Vox Sang. 2015, 109, 114–121. [Google Scholar] [CrossRef] [PubMed]
  16. Li, M.; Xu, Z.; Lu, J.; Zheng, H.; Ye, L.; Liu, Y.; Liu, Z.; Zhang, H.; Huang, Y.; Dai, E.; et al. Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. J. Viral Hepat. 2020, 27, 1044–1051. [Google Scholar] [CrossRef] [PubMed]
  17. Liao, H.; Li, L.; Zheng, W.V.; Zou, J.; Yu, G.; Si, L.; Ge, F.; Zhou, T.; Ji, D.; Chen, X.; et al. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Dis. Markers 2022, 2022, 4133283. [Google Scholar] [CrossRef] [PubMed]
  18. Hottenträger, B.; Hagedorn, H.-J.; Bäcker, E.; Bleekmann, B.; Gessner, A.; Lübke, N.; Wenzel, J.; Widera, M.; Pabinger, S.; Ramge, P.; et al. Multicenter Performance Evaluation of Elecsys Anti-HBc II, Anti-HCV II, HIV combi PT, HBsAg II, and Syphilis Immunoassays. Clin. Lab. 2021, 67, 2594–2599. [Google Scholar] [CrossRef]
  19. Zhang, Z.-Q.; Shi, B.-S.; Lu, W.; Huang, D.; Wang, Y.-B.; Feng, Y.-L. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J. Virol. Methods 2021, 296, 114226. [Google Scholar] [CrossRef]
  20. Hourfar, M.K.; Walch, L.A.; Geusendam, G.; Dengler, T.; Janetzko, K.; Gubbe, K.; Frank, K.; Karl, A.; Löhr, M.; Sireis, W.; Seifried, E.; Schmidt, M. Sensitivity and specificity of Anti-HBc screening assays--which assay is best for blood donor screening? Int. J. Lab. Hematol. 2009, 31, 649–656. [Google Scholar] [CrossRef]
  21. Maugard, C.; Relave, J.; Klinkicht, M.; Fabra, C. Clinical performance evaluation of Elecsys HIV Duo, Anti-HCV II, HBsAg II, Anti-HBc II, and Syphilis assays for routine screening of first-time blood donor samples at a French blood donation center. Transfus. Clin. et Biol. 2022, 29, 79–83. [Google Scholar] [CrossRef]
  22. Li, L.; Han, T.; Zang, L.; Niu, L.; Cheng, W.; Lin, H.; Li, K.Y.; Cao, R.; Zhao, B.; Liu, Y.; et al. The current incidence, prevalence, and residual risk of hepatitis B viral infections among voluntary blood donors in China. BMC Infect. Dis. 2017, 17, 754. [Google Scholar] [CrossRef] [PubMed]
  23. Juhl, D.; Knobloch, J.K.-M.; Görg, S.; Hennig, H. Comparison of Two Test Strategies for Clarification of Reactive Results for Anti-HBc in Blood Donors. Transfus. Med. Hemotherapy 2016, 43, 37–43. [Google Scholar] [CrossRef] [PubMed]
  24. Bahari, A.; Izadi, S.; Bari, Z.; Khosravi, S.; Baghaei, B.; Saneimoghadam, E.; Firouzi, F.; Espiari, A.; Esmaeilzadeh, A.; Mokhtarifar, A.; et al. Significance of Response to Hepatitis B Recombinant Vaccine in Subjects with Isolated Antibody to Hepatitis B Core Antigen. Middle. East. J. Dig. Dis. 2015, 7, 233–240.
  25. Wu, T.; Kwok, R.M.; Tran, T.T. Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody—A Review of New Issues. Am. J. Gastroenterol. 2017, 112, 1780–1788. [Google Scholar] [CrossRef] [PubMed]
  26. Wang, Q.; Klenerman, P.; Semmo, N. Significance of anti-HBc alone serological status in clinical practice. Lancet Gastroenterol. Hepatol. 2017, 2, 123–134. [Google Scholar] [CrossRef]
  27. Querido, S.; Weigert, A.; Adragão, T.; Rodrigues, L.; Jorge, C.; Bruges, M.; Machado, D. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transpl. Infect. Dis. 2019, 21, e13009. [Google Scholar] [CrossRef] [PubMed]
  28. Pei, R.; Grund, S.; Verheyen, J.; Esser, S.; Chen, X.; Lu, M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-Hepatitis B core antibodies. Virol. J. 2014, 11, 9. [Google Scholar] [CrossRef] [PubMed]
  29. Witt, M.D.; Lewis, R.J.; Rieg, G.; Seaberg, E.C.; Rinaldo, C.R.; Thio, C.L. Predictors of the Isolated Hepatitis B Core Antibody Pattern in HIV-Infected and -Uninfected Men in the Multicenter AIDS Cohort Study. Clin. Infect. Dis. 2013, 56, 606–612. [Google Scholar] [CrossRef] [PubMed]
  30. Azarkar, Z.; Ziaee, M.; Ebrahimzadeh, A.; Sharifzadeh, G.; Javanmard, D. Epidemiology, risk factors, and molecular characterization of occult hepatitis B infection among anti-hepatitis B core antigen alone subjects. J. Med. Virol. 2019, 91, 615–622. [Google Scholar] [CrossRef] [PubMed]
  31. Mardian, Y.; Yano, Y.; Wasityastuti, W.; Ratnasari, N.; Liang, Y.; Putri, W.A.; Triyono, T.; Hayashi, Y. Genetic polymorphisms of HLA-DP and isolated anti-HBc are important subsets of occult hepatitis B infection in Indonesian blood donors: a case-control study. Virol. J. 2017, 14, 201. [Google Scholar] [CrossRef] [PubMed]
  32. Sohn, W.; Chang, Y.; Cho, Y.K.; Hong, Y.S.; Ryu, S. Isolated Hepatitis B Core Antibody Positivity and Long-Term Liver-Related Mortality in Korea: A Cohort Study. Am. J. Gastroenterol. 2023, 118, 95–104. [Google Scholar] [CrossRef]
  33. Liao, H.; Li, L.; Zheng, W.V.; Zou, J.; Yu, G.; Si, L.; Ge, F.; Zhou, T.; Ji, D.; Chen, X.; et al. Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients. Dis. Markers 2022, 2022, 4133283. [Google Scholar] [CrossRef]
  34. Fang, Y.Q.; Xu, X.Y.; Hou, F.Q.; Jia, W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antivir. Ther. 2021, 26, 126–133. [Google Scholar] [CrossRef] [PubMed]
  35. Wang, X.; Zhang, Y.; Ben, Y.; Qiu, C.; Wu, J.; Zhang, W.; Wan, Y. Anti-HBc IgG Responses Occurring at the Early Phase of Infection Correlate Negatively with HBV Replication in a Mouse Model. Viruses 2022, 14, 2011. [Google Scholar] [CrossRef]
  36. Zhao, X.-A.; Wang, J.; Liu, J.; Chen, G.; Yan, X.; Jia, B.; Yang, Y.; Liu, Y.; Gu, D.; Zhang, Z.; et al. Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment. Antivir. Res. 2021, 193, 105146. [Google Scholar] [CrossRef]
  37. Chi, H.; Li, Z.; Hansen, B.E.; Yu, T.; Zhang, X.; Sun, J.; Hou, J.; Janssen, H.L.; Peng, J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin. Gastroenterol. Hepatol. 2019, 17, 182–191.e1. [Google Scholar] [CrossRef]
  38. Wang, W.-X.; Jia, R.; Gao, Y.-Y.; Liu, J.-Y.; Luan, J.-Q.; Qiao, F.; Liu, L.-M.; Zhang, X.-N.; Wang, F.-S.; Fu, J. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients. Front. Immunol. 2022, 13, 894410. [Google Scholar] [CrossRef]
  39. Li, J.; Gong, Q.M.; Xie, P.L.; Lin, J.Y.; Chen, J.; Wei, D.; Yu, D.M.; Han, Y.; Zhang, X.X. Prognostic value of anti-HBc quantification in hepatitis B virus related acute-on-chronic liver failure. J. Gastroenterol. Hepatol. 2021, 36, 1291–1299. [Google Scholar] [CrossRef]
  40. Kan, K.; Wong, D.K.-H.; Hui, R.W.-H.; Seto, W.K.; Yuen, M.-F.; Mak, L.-Y. Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study. BMC Gastroenterol. 2023, 23, 348. [Google Scholar] [CrossRef] [PubMed]
  41. Hu, H.-H.; Liu, J.; Chang, C.-L.; Jen, C.-L.; Lee, M.-H.; Lu, S.-N.; Wang, L.-Y.; Quan, Y.; Xia, N.-S.; Chen, C.-J.; et al. Level of Hepatitis B (HB) Core Antibody Associates With Seroclearance of HBV DNA and HB Surface Antigen in HB e Antigen-Seronegative Patients. Clin. Gastroenterol. Hepatol. 2019, 17, 172–181.e1. [Google Scholar] [CrossRef] [PubMed]
  42. Ohki, T.; Tateishi, R.; Goto, E.; Sato, T.; Masuzaki, R.; Imamura, J.; Goto, T.; Kanai, F.; Kato, N.; Shiina, S.; et al. Influence of anti-HBc seropositivity on the risk of hepatocellular carcinoma in HCV-infected patients after adjusting for confounding factors. J. Viral Hepat. 2010, 17, 91–97. [Google Scholar] [CrossRef] [PubMed]
  43. Tsubouchi, N.; Uto, H.; Kumagai, K.; Sasaki, F.; Kanmura, S.; Numata, M.; Moriuchi, A.; Oketani, M.; Ido, A.; Hayashi, K.; et al. Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study. Hepatol. Res. 2013, 43, 1130–1138. [Google Scholar] [CrossRef] [PubMed]
  44. Lok, A.S.; Everhart, J.E.; Di Bisceglie, A.M.; Kim, H.-Y.; Hussain, M.; Morgan, T.R. The HALT-C Trial Group Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. J. Hepatol. 2011, 54, 434–442. [Google Scholar] [CrossRef]
  45. Coppola, N.; Onorato, L.; Sagnelli, C.; Sagnelli, E.; Angelillo, I.F. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016; 95(30), e4311.
  46. Wang, H.; Swann, R.; Thomas, E.; Innes, H.A.; Valerio, H.; Hayes, P.C.; Allen, S.; Barclay, S.T.; Wilks, D.; Fox, R.; et al. Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis. J. Viral Hepat. 2018, 25, 930–938. [Google Scholar] [CrossRef] [PubMed]
  47. Chan, T.T.; Chan, W.K.; Wong, G.L.-H.; Chan, A.W.-H.; Mustapha, N.R.N.; Chan, S.L.; Chong, C.C.-N.; Mahadeva, S.; Shu, S.S.-T.; Lai, P.B.-S.; et al. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am. J. Gastroenterol. 2020, 115, 867–875. [Google Scholar] [CrossRef] [PubMed]
  48. El-Maksoud, M.A.; Habeeb, M.R.; Ghazy, H.F.; Nomir, M.M.; Elalfy, H.; Abed, S.; Zaki, M.E. Clinicopathological study of occult hepatitis B virus infection in hepatitis C virus-associated hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 2019, 31, 716–722. [Google Scholar] [CrossRef] [PubMed]
  49. VoPham, T.; Cravero, A.; Feld, L.D.; Green, P.; Feng, Z.; Berry, K.; Kim, N.J.; Vutien, P.; Mendoza, J.A.; Ioannou, G.N. Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis. Cancer Epidemiol. Biomarkers Prev. 2023, 32, 1069–1078. [Google Scholar] [CrossRef]
  50. Hui, C-K.; Cheung, W.W.; Zhang, H-Y.; Au, W-Y.; Yueng, Y-H.; Leung, A.Y.H.; Leung, N.; Luk, J.M.; Lie, A.K.W.; Kwong, Y-L.; Liang, R.; Lau, G.K. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gasteroenterol. 2006, 131, 59–68. [Google Scholar] [CrossRef] [PubMed]
  51. Umemura, T.; Tanaka, E.; Kiyosawa, K.; Kumada, H. ; Japan de novo Hepatitis B Research Group Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan. Clin. Infect. Dis. 2008, 47, e52–e56. [Google Scholar] [CrossRef]
  52. Tanaka, E.; Umemura, T. History and prevention of de novo hepatitis B virus-related hepatitis in Japan and the world. Clin. J. Gastroenterol. 2008, 1, 83–86. [Google Scholar] [CrossRef]
  53. Kusumoto, S.; Tanaka, Y.; Mizokami, M.; Ueda, R. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int. J. Hematol. 2009, 90, 13–23. [Google Scholar] [CrossRef]
  54. Lalazar, G.; Rund, D.; Shouval, D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with hematological malignancies. Br. J. Hematol. 2007, 136, 699–712. [Google Scholar] [CrossRef]
  55. Liu, Y.; Nuersulitan, R.; Zhang, C.; Huo, N.; Li, J.; Song, Y.; Zhu, J.; Liu, W.; Zhao, H. Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation. J. Clin. Med. 2023, 13 :23.
  56. Lasagna, A.; Albi, G.; Maserati, R.; Zuccarini, A.; Quaccini, M.; Baldanti, F.; Sacchi, P.; Bruno, R.; Pedrazzoli, P. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study. Front. Oncol. 2023, 13, 1044098. [Google Scholar] [CrossRef] [PubMed]
  57. Xia, Z.; Zhang, J.; Chen, W.; Zhou, H.; Du, D.; Zhu, K.; Chen, H.; Meng, J.; Yang, J. Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Infect. Dis. Poverty 2023, 12, 87. [Google Scholar] [CrossRef]
  58. Clarke, W.T.; Amin, S.S.; Papamichael, K.; Feuerstein, J.D.; Cheifetz, A.S. Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg−) on anti-TNF therapy have a low rate of reactivation. Clin. Immunol. 2018, 191, 59–62. [Google Scholar] [CrossRef] [PubMed]
  59. Uemoto, S.; Sugiyama, K.; Marusawa, H.; Inomata, Y.; Asonuma, K.; Egawa, H.; Kiuchi, T.; Miyake, Y.; Tanaka, K.; Chiba, T. Transmission of hepatitis B virus from hepatitis B core antibody‐positive donors in living related liver transplants. Transplantation 1998, 65, 494–499. [Google Scholar] [CrossRef]
  60. Joya-Vazquez, P.P.; Dodson, F.S.; Dvorchik, I.; Gray, E.; Chesky, A.; Demetris, A.J.; Shakil, O.; Fung, J.J.; Vargas, H.E. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002, 73, 1598–1602. [Google Scholar] [CrossRef] [PubMed]
  61. Cholongitas, E.; Papatheodoridis, G.V.; Burroughs, A.K. Liver grafts from anti-hepatitis B core positive donors: A systematic review. J. Hepatol. 2010, 52, 272–279. [Google Scholar] [CrossRef]
  62. Roche, B.; Roque-Afonso, A.-M.; Sebagh, M.; Delvart, V.; Duclos-Vallee, J.C.; Castaing, D.; Samuel, D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transplant. 2010, 16, 885–894. [Google Scholar] [CrossRef]
  63. Ueda, Y.; Marusawa, H.; Egawa, H.; Okamoto, S.; Ogura, Y.; Oike, F.; Nishijima, N.; Takada, Y.; Uemoto, S.; Chiba, T. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir. Ther. 2011, 16, 479–487. [Google Scholar] [CrossRef]
  64. Maiwall, R.; Kumar, M. Prevention and Treatment of Recurrent Hepatitis B after Liver Transplantation. J. Clin. Transl. Hepatol. 2016, 4, 54–65. [Google Scholar] [CrossRef]
  65. Wong, T.C.-L.; Fung, J.Y.-Y.; Cui, T.Y.-S.; Lam, A.H.-K.; Dai, J.W.-C.; Chan, A.C.-Y.; Cheung, T.-T.; Chok, K.S.-H.; Ng, K.K.-C.; Lo, C.-M. Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis. J. Hepatol. 2019, 70, 1114–1122. [Google Scholar] [CrossRef]
  66. Kim, K.D.; Lee, J.E.; Kim, J.M.; Lee, O.; Hwang, N.Y.; Rhu, J.; Choi, G.-S.; Kim, K.; Joh, J.-W. Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea. Clin. Mol. Hepatol. 2021, 27, 603–615. [Google Scholar] [CrossRef]
  67. Querido, S.; Weigert, A.; Adragão, T.; Rodrigues, L.; Jorge, C.; Bruges, M.; Machado, D. Risk of hepatitis B reactivation in hepatitis B surface antigen seronegative and core antibody seropositive kidney transplant recipients. Transpl. Infect. Dis. 2019, 21, e13009. [Google Scholar] [CrossRef] [PubMed]
  68. Holtkamp, C.; Fiedler, M.; Dittmer, U.; Anastasiou, O.E. The Course of Anti-HBc Antibodies over Time in Immunocompromised Hosts. Vaccines 2022, 10, 137. [Google Scholar] [CrossRef] [PubMed]
  69. Kimura, T.; Rokuhara, A.; Sakamoto, Y.; Yagi, S.; Tanaka, E.; Kiyosawa, K.; Maki, N. Sensitive Enzyme Immunoassay for Hepatitis B Virus Core-Related Antigens and Their Correlation to Virus Load. J. Clin. Microbiol. 2002, 40, 439–445. [Google Scholar] [CrossRef]
  70. Kimura, T.; Ohno, N.; Terada, N.; Rokuhara, A.; Matsumoto, A.; Yagi, S.; Tanaka, E.; Kiyosawa, K.; Ohno, S.; Maki, N. Hepatitis B Virus DNA-negative Dane Particles Lack Core Protein but Contain a 22-kDa Precore Protein without C-terminal Arginine-rich Domain. J. Biol. Chem. 2005, 280, 21713–21719. [Google Scholar] [CrossRef] [PubMed]
  71. Yuen, M-F.; Chen, D-S.; Dusheiko, G.M.; Janssen, H.L.A.; Lau, D.T.Y.; Locarnini, S.A.; Peters, M.G.; Lai, C-L. Hepatitis B virus infection. Nat Rev. 2018; 4: 1–20.
  72. Mak, L.; Wong, D.K.; Cheung, K.; Seto, W.; Lai, C.; Yuen, M. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment. Pharmacol. Ther. 2018, 47, 43–54. [Google Scholar] [CrossRef]
  73. Wong, D.K.; Seto, W.; Cheung, K.; Chong, C.; Huang, F.; Fung, J.; Lai, C.; Yuen, M. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017, 37, 995–1001. [Google Scholar] [CrossRef]
  74. Suzuki, F.; Miyakoshi, H.; Kobayashi, M.; Kumada, H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J. Med Virol. 2009, 81, 27–33. [Google Scholar] [CrossRef]
  75. Chen, E.-Q.; Feng, S.; Wang, M.-L.; Liang, L.-B.; Zhou, L.-Y.; Du, L.-Y.; Yan, L.-B.; Tao, C.-M.; Tang, H. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci. Rep. 2017, 7, 173. [Google Scholar] [CrossRef] [PubMed]
  76. Lam, Y.-F.; Seto, W.-K.; Wong, D.; Cheung, K.-S.; Fung, J.; Mak, L.-Y.; Yuen, J.; Chong, C.-K.; Lai, C.-L.; Yuen, M.-F. Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. Clin. Transl. Gastroenterol. 2017, 8, e125. [Google Scholar] [CrossRef] [PubMed]
  77. Testoni, B.; Lebossé, F.; Scholtes, C.; Berby, F.; Miaglia, C.; Subic, M.; Loglio, A.; Facchetti, F.; Lampertico, P.; Levrero, M.; et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 2019, 70, 615–625. [Google Scholar] [CrossRef] [PubMed]
  78. Inoue, T.; Kusumoto, S.; Iio, E.; Ogawa, S.; Suzuki, T.; Yagi, S.; Kaneko, A.; Matsuura, K.; Aoyagi, K.; Tanaka, Y. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J. Hepatol. 2021, 75, 302–310. [Google Scholar] [CrossRef]
  79. Kuhns, M.C.; Holzmayer, V.; McNamara, A.L.; Anderson, M.; Cloherty, G.A. Hepatitis B seroconversion revisited: new insights into the natural history of acute hepatitis B virus (HBV) infection from quantitative and highly sensitive assays and novel biomarkers. Virol. J. 2021, 18, 235. [Google Scholar] [CrossRef] [PubMed]
  80. Gou, Y.; Zhao, Y.; Rao, C.; Feng, S.; Wang, T.; Li, D.; Tao, C. Predictive Value of Hepatitis B Core-Related Antigen (HBcrAg) During the Natural History of Hepatitis B Virus Infection. Clin. Lab. 2017, 63, 1063–1070. [Google Scholar] [CrossRef] [PubMed]
  81. Ghany, M.G.; King, W.C.; Lisker-Melman, M.; Lok, A.S.; Terrault, N.; Janssen, H.L.; Khalili, M.; Chung, R.T.; Lee, W.M.; Lau, D.T.; et al. Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America. J. Hepatol. 2021, 74, 2395–2409. [Google Scholar] [CrossRef] [PubMed]
  82. Seto, W.-K.; Wong, D.K.-H.; Fung, J.; Huang, F.-Y.; Liu, K.S.-H.; Lai, C.-L.; Yuen, M.-F. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin. Microbiol. Infect. 2014, 20, 1173–1180. [Google Scholar] [CrossRef]
  83. Maasoumy, B.; Wiegand, S.; Jaroszewicz, J.; Bremer, B.; Lehmann, P.; Deterding, K.; Taranta, A.; Manns, M.; Wedemeyer, H.; Glebe, D.; et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin. Microbiol. Infect. 2015, 21, 606. e1-10. [Google Scholar] [CrossRef]
  84. Loggi, E.; Vukotic, R.; Conti, F.; Grandini, E.; Gitto, S.; Cursaro, C.; Galli, S.; Furlini, G, Re M.C.; Andreone, P. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B. J. Viral. Hepat. 2019, 26, 568–575. [Google Scholar] [CrossRef]
  85. Mak, L.-Y.; Wong, D.K.-H.; Cheung, K.-S.; Seto, W.-K.; Fung, J.; Yuen, M.-F. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol. 2021, 21, 1–7. [Google Scholar] [CrossRef]
  86. Tsai, Y.-N.; Wu, J.-L.; Tseng, C.-H.; Chen, T.-H.; Wu, Y.-L.; Chen, C.-C.; Fang, Y.-J.; Yang, T.-H.; Nguyen, M.H.; Lin, J.-T.; et al. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. Clin. Mol. Hepatol. 2024, 30, 98–108. [Google Scholar] [CrossRef]
  87. Adraneda, C.; Tan, Y.C.; Yeo, E.J.; Kew, G.S.; Khakpoor, A.; Lim, S.G. A critique and systematic review of the clinical utility of hepatitis B core-related antigen. J. Hepatol. 2023, 78, 731–741. [Google Scholar] [CrossRef] [PubMed]
  88. Kaneko, S.; Kurosaki, M.; Inada, K.; Kirino, S.; Hayakawa, Y.; Yamashita, K.; Osawa, L.; Sekiguchi, S.; Higuchi, M.; Takaura, K.; et al. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J. Gastroenterol. Hepatol. 2021, 36, 2943–2951. [Google Scholar] [CrossRef] [PubMed]
  89. Liang, L.Y.; Wong, V.W.-S.; Toyoda, H.; Tse, Y.-K.; Yip, T.C.-F.; Yuen, B.W.-Y.; Tada, T.; Kumada, T.; Lee, H.-W.; Lui, G.C.-Y.; et al. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J. Gastroenterol. 2020, 55, 899–908. [Google Scholar] [CrossRef]
  90. Chang, K.-C.; Lin, M.-T.; Wang, J.-H.; Hung, C.-H.; Chen, C.-H.; Chiu, S.Y.-H.; Hu, T.-H. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral. Viruses 2022, 14, 2671. [Google Scholar] [CrossRef]
  91. Tseng, T.-C.; Liu, C.-J.; Hsu, C.-Y.; Hong, C.-M.; Su, T.-H.; Yang, W.-T.; Chen, C.-L.; Yang, H.-C.; Huang, Y.-T.; Kuo, S.F.-T.; et al. High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology 2019, 157, 1518–1529 e3. [Google Scholar] [CrossRef]
  92. Hsieh, Y.-C.; Pan, M.-H.; Jeng, W.-J.; Hu, H.-H.; Liu, J.; Mizokami, M.; Chen, C.-J.; Yang, H.-I. Serum HBcrAg and Hepatocellular Carcinoma in a Taiwanese Population Seronegative for HBsAg and Anti-HCV. Clin. Gastroenterol. Hepatol. 2023, 21, 1303–1313. [Google Scholar] [CrossRef] [PubMed]
  93. Cheung, K.; Seto, W.; Wong, D.K.; Lai, C.; Yuen, M. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J. Viral Hepat. 2017, 24, 654–661. [Google Scholar] [CrossRef]
  94. Hosaka, T.; Suzuki, F.; Kobayashi, M.; Fujiyama, S.; Kawamura, Y.; Sezaki, H.; Akuta, N.; Suzuki, Y.; Saitoh, S.; Arase, Y.; et al. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment. Pharmacol. Ther. 2019, 49, 457–471. [Google Scholar] [CrossRef]
  95. To W, Mak L, Wong DK, Fung J, Liu F, Seto W, Lai C, Yuen M; Hepatitis B core-related antigen levels after HbeAg seroconversion is associated with the development of hepatocellular carcinoma. J. Viral Hepat. 2019, 26, 1473–1480. [CrossRef] [PubMed]
  96. Hosaka, T.; Suzuki, F.; Kobayashi, M.; Fujiyama, S.; Kawamura, Y.; Sezaki, H.; Akuta, N.; Kobayashi, M.; Suzuki, Y.; Saitoh, S.; et al. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. Hepatol. Commun. 2022, 6, 36–49. [Google Scholar] [CrossRef] [PubMed]
  97. Hagiwara, S.; Kusumoto, S.; Inoue, T.; Ogawa, S.; Narita, T.; Ito, A.; Ri, M.; Komatsu, H.; Suzuki, T.; Matsuura, K.; et al. Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay. Hepatol. Res. 2022, 52, 745–753. [Google Scholar] [CrossRef] [PubMed]
  98. Suzuki, T.; Inoue, T.; Matsuura, K.; Kusumoto, S.; Hagiwara, S.; Ogawa, S.; Yagi, S.; Kaneko, A.; Fujiwara, K.; Watanabe, T.; et al. Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation. J. Gastroenterol. 2022, 57, 486–494. [Google Scholar] [CrossRef]
  99. Mak, L.-Y.; Wong, D.K.-H.; Seto, W.-K.; Lai, C.-L.; Yuen, M.F. Hepatitis B core protein as a therapeutic target. Expert Opin. Ther. Targets 2017, 21, 1153–1159. [Google Scholar] [CrossRef]
  100. Lam, A.M.; Ren, S.; Espiritu, C.; Kelly, M.; Lau, V.; Zheng, L.; Hartman, G.D.; Flores, O.A.; Klumpp, K. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants. Antimicrob. Agents Chemother. 2017, 61, e00680–17. [Google Scholar] [CrossRef] [PubMed]
  101. McFadden, W.M.; Sarafianos, S.G. Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure. Glob. Health Med. 2023, 5, 199–207. [Google Scholar] [CrossRef]
  102. Kuduk, S.D.; Stoops, B.; Alexander, R.; Lam, A.M.; Espiritu, C.; Vogel, R.; Lau, V.; Klumpp, K.; Flores, O.A.; Hartman, G.D. Identification of a new class of HBV capsid assembly modulator. Bioorganic Med. Chem. Lett. 2021, 39, 127848. [Google Scholar] [CrossRef] [PubMed]
  103. Kim, H.; Ko, C.; Lee, J.-Y.; Kim, M. Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. Molecules 2021, 26, 7420. [Google Scholar] [CrossRef]
  104. Yang, L.; Liu, F.; Tong, X.; Hoffmann, D.; Zuo, J.; Lu, M. Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and Perspectives. ACS Infect. Dis. 2019, 5, 713–724. [Google Scholar] [CrossRef]
  105. Amblard, F.; Chen, Z.; Wiseman, J.; Zhou, S.; Liu, P.; Salman, M.; Verma, K.; Azadi, N.; Downs-Bowen, J.; Tao, S.; et al. Synthesis and evaluation of highly potent HBV Capsid Assembly Modulators (CAMs). Bioorganic Chem. 2023, 141, 106923. [Google Scholar] [CrossRef] [PubMed]
Table 1. Common anti-HBc antibody assay techniques.
Table 1. Common anti-HBc antibody assay techniques.
Product name Manufacturer Method Positive range Unit Ref.
ADVIA Centaur® HBc Total 2 assay Bayer Diagnostics CLIA ≥1.0 Index 8,9
MUREX anti-HBc DiaSorin ELISA 10
MONOLISA anti-HBc EIA Bio-Rad EIA ≥0.5 Index 10,11
ORTHO HBc ELISA test Ortho-Clinical Diagnostics ELISA 12
Lumipulse HBcAb-N® Fujirebio CLEIA ≥1.0 COI 13
Elecsys®, Anti-HBc Roche ECLIA <1.0 COI 14,15
CLIA Microparticles Autobio Diagnostics, Zhengzhou CLIA 16
ARCHITECT® HBc II Abbott Diagnostics CMIA ≥1.0 S/CO 17
HBcAb ELISA Wantai Biological Pharmacy Enterprise Company ELISA ≥1.0 IU/mL 18
InnoDx Biotech CMIA IU/mL 19
CLIA: chemiluminescent immunoassay; ELISA: enzyme-linked immunosorbent assay; EIA: enzyme immunoassay; CLEIA: chemiluminescent enzyme immunoassay; ECLIA: electro chemiluminescence immunoassay; COI: cut-off index; S/CO: sample cut-off; IU: international units.
Table 2. Comparison of Lumpulse HBcrAg and Lumpulse presto iTACT HBcrAg.
Table 2. Comparison of Lumpulse HBcrAg and Lumpulse presto iTACT HBcrAg.
Lumpulse HBcrAg Lumpulse presto iTACT HBcrAg
Method 2-step sandwich assay (CLEIA) 2-step sandwich assay (CLEIA)
Sample volume 150 uL 50 uL
Measurement time 65 min 35 min
Range of measurement 3.0 to 7.0 logU/mL 2.1 to 7.0 logU/mL
Target machine Lumpulse G600II/ Lumpulse G1200 Lumpulese L2400
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
bsky
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

Privacy Settings

© 2025 MDPI (Basel, Switzerland) unless otherwise stated